Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1803]
News [2707]
Articles [198]
Editorials [1]
Conferences [135]
elearning [13]
Trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer
Trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer
Study confirms fibrosis as a prognostic indicator in the most common breast cancer, and opens the way to antifibrotic drug treatments
Study confirms fibrosis as a prognostic indicator in the most common breast cancer, and opens the way to...
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer
ESMO 2024: Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to...
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukaemia
Novel triplet regimen yields promising response in advanced-phase chronic myeloid leukaemia
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Survival benefits from adding perioperative durvalumab to chemo in MIBC
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human trial
ESMO 2024: Novel ADC AZD8205 demonstrates manageable safety profile and preliminary efficacy in first-in-human...
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer
Researcher develops drug delivery system for chemo-induced hearing loss
Researcher develops drug delivery system for chemo-induced hearing loss
University develops novel bone cancer therapy which has 99% success rate
University develops novel bone cancer therapy which has 99% success rate

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation